HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[CD34+ progenitor cell transplantation from HLA-mismatched donors to two patients with chronic active Epstein-Barr virus infection].

Abstract
We report two boys with chronic active Epstein-Barr virus infection (CAEBV) refractory to conventional chemotherapy, who received HLA-mismatched allografts of CD34-positive progenitor cells from their fathers. One patient developed veno-occlusive disease (VOD) of the liver on day 18 after transplantation and died on day 26. The other patient received the allograft during partial remission. Although he suffered recurrent infections due to Streptococcus viridans, he is now doing well 23 months after transplantation. CAEBV refractory to chemotherapy is considered to be a fatal EBV-infected T/NK-cell lymphoproliferative disease, and our experiences suggest that CD34-positive progenitor cell transplantation for patients with CAEBV lacking HLA-matched donors may be a feasible and useful treatment. However, the timing of transplantation is considered to be critical, and should be performed when the patient is in good clinical condition.
AuthorsM Yasui, T Okamura, N Sakata, M Inoue, K Yagi, T Yoshimoto, O Mabuchi, M Sano, K Kawa
Journal[Rinsho ketsueki] The Japanese journal of clinical hematology (Rinsho Ketsueki) Vol. 42 Issue 11 Pg. 1111-6 (Nov 2001) ISSN: 0485-1439 [Print] Japan
PMID11808080 (Publication Type: Case Reports, English Abstract, Journal Article)
Chemical References
  • Antigens, CD34
Topics
  • Antigens, CD34 (immunology)
  • Child
  • Chronic Disease
  • Epstein-Barr Virus Infections (therapy, virology)
  • Hematopoietic Stem Cell Transplantation
  • Herpesvirus 4, Human
  • Histocompatibility (immunology)
  • Humans
  • Male
  • Transplantation, Homologous

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: